Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC2574677461;77462;77463 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
N2AB2410572538;72539;72540 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
N2A2317869757;69758;69759 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
N2B1668150266;50267;50268 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
Novex-11680650641;50642;50643 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
Novex-21687350842;50843;50844 chr2:178568896;178568895;178568894chr2:179433623;179433622;179433621
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: S
  • RefSeq wild type transcript codon: TCA
  • RefSeq wild type template codon: AGT
  • Domain: Fn3-75
  • Domain position: 49
  • Structural Position: 66
  • Q(SASA): 0.4435
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
S/L None None 0.989 N 0.571 0.403 0.485991781493 gnomAD-4.0.0 6.84455E-07 None None None None N None 0 0 None 0 0 None 0 0 8.99617E-07 0 0
S/P None None 0.999 N 0.703 0.367 0.307016933798 gnomAD-4.0.0 1.20033E-06 None None None None N None 0 0 None 0 0 None 0 0 1.31251E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
S/A 0.0864 likely_benign 0.0836 benign -0.604 Destabilizing 0.973 D 0.412 neutral N 0.468994131 None None N
S/C 0.1468 likely_benign 0.1354 benign -0.362 Destabilizing 1.0 D 0.693 prob.neutral None None None None N
S/D 0.5105 ambiguous 0.4463 ambiguous -0.001 Destabilizing 0.996 D 0.551 neutral None None None None N
S/E 0.5118 ambiguous 0.4413 ambiguous -0.05 Destabilizing 0.996 D 0.549 neutral None None None None N
S/F 0.2331 likely_benign 0.2059 benign -0.91 Destabilizing 1.0 D 0.707 prob.neutral None None None None N
S/G 0.1175 likely_benign 0.1101 benign -0.8 Destabilizing 0.996 D 0.492 neutral None None None None N
S/H 0.3781 ambiguous 0.3314 benign -1.208 Destabilizing 1.0 D 0.686 prob.neutral None None None None N
S/I 0.1527 likely_benign 0.1375 benign -0.204 Destabilizing 0.998 D 0.723 prob.delet. None None None None N
S/K 0.6648 likely_pathogenic 0.5782 pathogenic -0.71 Destabilizing 0.996 D 0.545 neutral None None None None N
S/L 0.1009 likely_benign 0.0954 benign -0.204 Destabilizing 0.989 D 0.571 neutral N 0.477960331 None None N
S/M 0.1588 likely_benign 0.1454 benign 0.023 Stabilizing 1.0 D 0.688 prob.neutral None None None None N
S/N 0.1442 likely_benign 0.1267 benign -0.487 Destabilizing 0.996 D 0.535 neutral None None None None N
S/P 0.8928 likely_pathogenic 0.8717 pathogenic -0.305 Destabilizing 0.999 D 0.703 prob.neutral N 0.479433407 None None N
S/Q 0.4602 ambiguous 0.402 ambiguous -0.676 Destabilizing 1.0 D 0.657 neutral None None None None N
S/R 0.6173 likely_pathogenic 0.5424 ambiguous -0.489 Destabilizing 0.999 D 0.705 prob.neutral None None None None N
S/T 0.0684 likely_benign 0.0653 benign -0.561 Destabilizing 0.543 D 0.287 neutral N 0.406945595 None None N
S/V 0.1478 likely_benign 0.1336 benign -0.305 Destabilizing 0.998 D 0.641 neutral None None None None N
S/W 0.4274 ambiguous 0.3848 ambiguous -0.893 Destabilizing 1.0 D 0.736 prob.delet. None None None None N
S/Y 0.2283 likely_benign 0.1992 benign -0.649 Destabilizing 1.0 D 0.705 prob.neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.